Back to Search Start Over

Analysis of lung cancer risk model (PLCOM2012 and LLPv2) performance in a community-based lung cancer screening programme

Authors :
Tom Newton
Richard Booton
Amanda Myerscough
Stuart Mellor
James Whittaker
Mikey B Lebrett
Peter Elton
Hilary A. Robbins
Anna Sharman
Denis Colligan
Haval Balata
Philip A.J. Crosbie
Devinda Karunaratne
P. Barber
Matthew Evison
Sarah Taylor
Elaine Smith
Anna Walsham
Melanie Greaves
Klaus L. Irion
Janet Tonge
J. Lyons
R. Duerden
Ben Taylor
John Howells
Source :
Lebrett, M, Balata, H, Evison, M, Colligan, D, Duerden, R, Elton, P, Greaves, M, Howells, J, Irion, K, Karunaratne, D, Lyons, J, Mellor, S, Myerscough, A, Newton, T, Sharman, A, Smith, E, Taylor, B, Taylor, S, Walsham, A, Whittaker, J, Barber, P V, Tonge, J, Robbins, H A, Booton, R & Crosbie, P 2020, ' Analysis of lung cancer risk model (PLCOM2012 and LLPv2) performance in a community-based lung cancer screening programme ', Thorax . https://doi.org/10.1136/thoraxjnl-2020-214626
Publication Year :
2020
Publisher :
BMJ, 2020.

Abstract

IntroductionLow-dose CT (LDCT) screening of high-risk smokers reduces lung cancer (LC) specific mortality. Determining screening eligibility using individualised risk may improve screening effectiveness and reduce harm. Here, we compare the performance of two risk prediction models (PLCOM2012 and Liverpool Lung Project model (LLPv2)) and National Lung Screening Trial (NLST) eligibility criteria in a community-based screening programme.MethodsEver-smokers aged 55–74, from deprived areas of Manchester, were invited to a Lung Health Check (LHC). Individuals at higher risk (PLCOM2012 score ≥1.51%) were offered annual LDCT screening over two rounds. LLPv2 score was calculated but not used for screening selection; ≥2.5% and ≥5% thresholds were used for analysis.ResultsPLCOM2012 ≥1.51% selected 56% (n=1429) of LHC attendees for screening. LLPv2 ≥2.5% also selected 56% (n=1430) whereas NLST (47%, n=1188) and LLPv2 ≥5% (33%, n=826) selected fewer. Over two screening rounds 62 individuals were diagnosed with LC; representing 87% (n=62/71) of 6-year incidence predicted by mean PLCOM2012 score (5.0%). 26% (n=16/62) of individuals with LC were not eligible for screening using LLPv2 ≥5%, 18% (n=11/62) with NLST criteria and 7% (n=5/62) with LLPv2 ≥2.5%. NLST eligible Manchester attendees had 2.5 times the LC detection rate than NLST participants after two annual screens (≈4.3% (n=51/1188) vs 1.7% (n=438/26 309); padjOR 2.50, 95% CI 1.11 to 5.64; p=0.028).ConclusionProspective comparisons of risk prediction tools are required to optimise screening selection in different settings. The PLCOM2012 model may underestimate risk in deprived UK populations; further research focused on model calibration is required.

Details

ISSN :
14683296 and 00406376
Volume :
75
Database :
OpenAIRE
Journal :
Thorax
Accession number :
edsair.doi.dedup.....d9fafa43964751b4b7c20f1380a456f2